Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

• Main Authors: Bruno Sangro (Author), Thomas Yau (Author), Anthony B. El‐Khoueiry (Author), Masatoshi Kudo (Author), Yun Shen (Author), Marina Tschaika (Author), Amit Roy (Author), Yan Feng (Author), Ling Gao (Author), Urvi Aras (Author)
• Format: Book
• Published: Wiley, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC). CheckMate 040 is an open‐label, multicohort, phase I/II trial in adults with advanced HCC that evaluate...